Vancouver, BC, Canada - August 21, 2019 - Aspect Biosystems has announced that they will present with collaborator JSR Corporation at Cell Symposia: Engineering Organoids and Organs to be held August 25-27, in San Diego, CA. The presentation will highlight milestone achievements to develop human liver tissue using Aspect’s microfluidic-based 3D bioprinting platform.
Aspect and JSR began their collaboration in 2018 and, following the achievement of all initial development milestones, have recently expanded their partnership to develop vascularized liver tissue. This includes Aspect providing access to its platform technology through the placement of an RX1™ 3D Bioprinter on-site at the JSR-Keio University Medical and Chemistry Innovation Center (JKiC) in Tokyo, Japan.
Presentation: Microfluidic-based bioprinting of perfusable, hollow liver tissue fibres for drug-induced liver injury testing
Date: Tuesday, August 27, 2019
Time: 11:55 AM
Location: Sunset Pavilion, Paradise Point Resort & Spa, San Diego, CA
Drug-induced liver injury (DILI) is the leading cause of late stage drug withdrawal in spite of standard preclinical animal testing. To enhance human-relevance for DILI testing, we generated perfusable, hollow tissue fibres containing human hepatocytes using a microfluidic-based bioprinting platform. These studies lay the foundation for the development of a human-relevant, 3D liver tissue assay that models how compounds are metabolized by hepatocytes within liver sinusoids.
About Cell Symposia: Engineering Organoids and Organs
The goal of this Cell Symposium is to bring scientists studying organoids and organ engineering together with bioengineers to discuss the exciting opportunities and challenges for engineering complexity in higher-order organ-like systems and to foster collaborations and synergize efforts toward generating cellular platforms that can address a myriad of unmet needs.
About Aspect Biosystems
Aspect Biosystems is a privately held biotechnology company pioneering microfluidic 3D bioprinting of living, human tissue. The company’s proprietary technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. In addition to its internal programs, Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to enable the creation of living, human tissues for medical research, therapeutic discovery, and regenerative medicine products.
About JSR Corporation
JSR Corporation is a multinational company with research-oriented organization that pursues close collaborations with leading innovators in a number of industries that are a key to the present and future welfare of human society: life sciences, synthetic rubbers, electronic materials, display and optical materials. JSR Corporation conducts its global life sciences business through its JSR Life Sciences Business Division. JSR Life Sciences provides specialized materials, products and services to the biotech industry both directly and through its subsidiaries Medical & Biological Laboratories Co. Ltd, KBI Biopharma, Inc., Selexis SA, and Crown Biosciences.Back to all